Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast, April 26-28, 2003, Philadelphia, Pennsylvania

Breast Journal

Volumn 10, Issue 4, 2004, Pages 273-294

  Schwartz, Gordon F ^a   Hortobagyi, Gabriel N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE;

ADVANCED CANCER; ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE MARKER; DRUG RESPONSE; HISTORY OF MEDICINE; HUMAN; LIFE EXPECTANCY; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; RADIATION DOSE; SKIN GRAFT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES;

EID: 3142658793     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21594.x     Document Type: Conference Paper

References (137)

1. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003;53:141-69.
2. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials [review]. Lancet 2002;359:909-19.
3. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
5. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189-96.
6. Fisher B, Carbone P, Economou SG, et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975;292:117-22.
7. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
8. Buzdar AU, Blumenschein GR, Krutchik AN, et al. Combined modality approach for inflammatory breast cancer: prolongation of disease-free interval and survival. Cancer Bull 1979;31:95.
9. Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-68.
10. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-59.
11. Haagensen CD, Stout AP. Carcinoma of the breast. Criteria of inoperability. Am Surg 1943;118:859-66.
12. Haagensen CD, Stout AP. Carcinoma of the breast. Criteria of inoperability. Am Surg 1943;118:1032-40.
13. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview [review]. Drugs 1997;54(suppl 4):1-7.
14. Hortobagyi GN, Buzdar AU. Locally advanced breast cancer: a review including the M.D. Anderson experience. In: Ragaz J, Ariel IM, eds. High-Risk Breast Cancer. Berlin: Springer-Verlag, 1991:382-415.
15. Jacquillat C, Weil M, Auclerc G, et al. Neo-adjuvant chemotherapy in the conservative management of breast cancers-study on 205 patients. In: Jacquillat C, Weil M, Khayat D. Neo-Adjuvant Chemotherapy. London: Libbey, 1986:197-206.
16. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119-29.
17. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-45.
18. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507-16.
19. Veronesi U, Valagussa P. Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 1981;47:170-75.
20. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.
21. Lacour J, Le M, Caceres E, Koszarowski T, Veronesi U, Hill C. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 1983;51:1941-43.
22. Fisher B, Montague E, Redmond C, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer 1977;39(suppl):2827-39.
23. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.
24. De La Garza JG, De La Huerta R, Torres R, Sanchez C. Different management of inflammatory breast carcinoma (chemo-RX-chemo)-experience in 18 cases during a 6 year period (1970-1976) [abstract C-32]. Proc Am Assoc Cancer Res 1977;18:274.
25. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
26. Bonadonna G, Valagussa P, Zucali R, Salvadori B. Primary chemotherapy in surgically resectable breast cancer [review]. CA Cancer J Clin 1995;45:227-43.
27. Schwartz GF, Cantor RI, Biermann WA. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. Arch Surg 1987;122:1430-34.
28. Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73:362-69.
29. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
30. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-69.
31. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease free survival in patients with locally advanced breast cancer. Am J Surg 1998;176:502-8.
32. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-81.
33. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
34. Skipper HE, Schabel FMJ, Mellett LB, et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970;54(pt 1):431-50.
35. Skipper HE. Adjuvant chemotherapy. Cancer 1978;41:936-40.
36. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976;60:1749-60.
37. Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer [review]. Cancer 1977;40(suppl):574-87.
38. Gundoz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861-65.
39. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.
40. NSABP. The effect of primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results NSABP protocol B-27 [abstract 5]. Breast Cancer Res Treat 2001;69:210.
41. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelenat H, Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 1993;29A:1843-48.
42. Makris A, Powles TJ, Allred DC, et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 1998;48:11-20.
43. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-63.
44. Buchholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003;9:33-41.
45. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.
46. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72-78.
47. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:1304-10.
48. Frye D, Buzdar A, Hortobagyi G. Prognostic significance of axillary nodal involvement after preoperative chemotherapy in stage III breast cancer [meeting abstract]. Proc Annu Meet Am Society Clin Oncol 1995;14:A81.
49. Breast. In: Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook, 6th ed. Philadelphia: Lippincott Raven, 2002:257-81.
50. Haagensen CD. A technique for radical mastectomy. Surgery 1946;19:100-31.
51. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992;69:2849-52.
52. Lesnick G, Perloff M, Korzun A, et al. Combination chemotherapy prior to surgery or radiotherapy in locally advanced breast cancer. In: Jacquillat C, Weil M, Khayat D. Neo-Adjuvant Chemotherapy. Paris: Libbey, 1986:207-11.
53. Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889-94.
54. Cocconi G, di Blasio B, Bisagni G, Alberti G, Botti E, Anghinoni E. Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. Am J Clin Oncol 1990;13:226-32.
55. Bonadonna G, Valagussa P, Brambilla C, Moliterni A, Zambetti M, Ferrari L. Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy [review]. Semin Oncol 1991;18:515-24.
56. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer [corrected and republished article originally printed in Eur J Cancer 1993;29A:592-5]. Eur J Cancer 1993;29A:1796-99.
57. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer [corrected and republished article originally printed in Eur J Cancer 1993;29A:592-5]. Eur J Cancer 1993;29A:1796-99.
58. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-29.
59. Veronesi U. NIH consensus meeting on early breast cancer [review]. Eur J Cancer 1990;26:843-44.
60. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96-102.
61. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer [review]. J Clin Oncol 2001;19:3817-27.
62. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from NSABP protocol B-27. J Clin Oncol 2003;24:4165-74.
63. Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999;17:855-61.
64. Burn I. Primary endocrine therapy of advanced local breast cancer [review]. Endocr Rel Cancer 1985;16(suppl):5-8.
65. Anderson EDC, Forrest APM, Levack PA, Cherry U, Hawkins RA. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer 1989;60:223-26.
66. Cheung KL, Howell A, Robertson JF. Preoperative endocrine therapy for breast cancer [review]. Endocr Rel Cancer 2000;7:131-41.
67. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000;6:2229-35.
68. Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001;66:191-99.
69. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16.
70. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7:1230-36.
71. Mauriac L, Debled M, Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 2002;13:293-98.
72. Hoff PM, Valero V, Buzdar AU, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 2000;88:2054-60.
73. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-32.
74. Gazet JC, Markopoulos C, Ford HT, Coombes RC, Bland JM, Dixon RC. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet 1988;1:679-81.
75. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective [review]. Eur J Cancer 2002;38:2214-21.
76. Kenny FS, Robertson JFR, Ellis IO, Elston CW, Blamey RW. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 1998;7:335-39.
77. Robertson JF, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992;28A:908-10.
78. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
79. Shin HJ, Sneige N. Is a diagnosis of infiltrating versus in situ ductal carcinoma of the breast possible in fine-needle aspiration specimens? Cancer 1998;84:186-91.
80. Smith BL. Approaches to breast-cancer staging [editorial]. N Engl J Med 2000;342:580-81.
81. Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibility. Ann Surg Oncol 2002;9:228-34.
82. Kuerer HM, Singletary SE, Buzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 2001;182:601-8.
83. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks [review]. Cancer 2003;98:1150-60.
84. Edeiken BS, Fornage BD, Bedi DG, et al. US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology 1999;213:895-900.
85. Newman LA, Kuerer HM, Fornage B, et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001;181:313-18.
86. Boerner S, Fornage BD, Singletary E, Sneige N. Ultrasound-guided fine-needle aspiration (FNA) of nonpalpable breast lesions: a review of 1885 FNA cases using the National Cancer Institute-supported recommendations on the uniform approach to breast FNA. Cancer 1999;87:19-24.
87. Fornage BD, Coan JD, David CL. Ultrasound-guided needle biopsy of the breast and other interventional procedures [review]. Radiol Clin N Am 1992;30:167-85.
88. Merchant TE, Obertop H, de Graaf PW. Advantages of magnetic resonance imaging in breast surgery treatment planning. Breast Cancer Res Treat 1993;25:257-64.
89. Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 1995;196:115-22.
90. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999;17:110-19.
91. Hylton N. Dedicated Breast MRI Systems Working Group report. J Magn Reson Imaging 1999;10:1006-9.
92. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002;179:1193-99.
93. Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000;83:1480-87.
94. Brady EW. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 2002;8:97-100.
95. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9:235-42.
96. Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000;88:2540-45.
97. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480-86.
98. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 2000;24:1266-72.
99. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000;89:2187-94.
100. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy [review]. Surg Clin N Am 2003;83:931-42.
101. Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 2003;9:374-79.
102. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001 [review]. Oncologist 2001;6:376-85.
103. Hortobagyi GN. Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr 2001;30:72-79.
104. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
105. Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 [abstract 12]. Proc Annu Meet Am Soc Clin Oncol 2003;22:4.
106. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002;8:1073-79.
107. Nabholtz J-M, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) with FAC (5-Fluorouracil, Doxorubicin, Cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study [abstract]. Proc Am Soc Clin Oncol 2002;:21.
108. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer-a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977;39:1289-94.
109. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001;74:983-86.
110. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000;92:179-81.
111. Hortobagyi GN, Buzdar A, Holmes FA, et al. Non-cross resistant adjuvant chemotherapy in the multidisciplinary management of locally advanced breast cancer [abstract 14]. Proceedings of the 7th International Congress on Anti-Cancer Treatment, February 3-6, 1997, Paris, France.
112. Hortobagyi G, Holmes F, Frye D, et al. Comparison of two adjuvant chemotherapy programs for locally advanced breast cancer: a prospective randomized trial [abstract 77]. Proc Am Soc Clin Oncol 1990;9:21.
113. Buchholz TA, Hill BS, Tucker SL, et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 2001;7:413-20.
114. Baillet F, Rozec C, Ucla L, Chauveinc L, Housset M, Weil M. Treatment of locally advanced breast cancer without mastectomy. 5- and 10-year results of 135 tumors larger than 5 centimeters treated by external beam therapy, brachytherapy, and neoadjuvant chemotherapy. Ann N Y Acad Sci 1993;698:264-70.
115. Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): effects of primary systemic therapy on local-regional disease [abstract 132]. Proc Annu Meet Am Soc Clin Oncol 2002;21:34a.
116. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer [review]. Clin Cancer Res 2003;9:10S.
117. Osteen RT. Selection of patients for breast conserving surgery. Cancer 1994;74:366-71.
118. NIH Consensus Development Conference on the Treatment of Early-Stage Breast Cancer. Bethesda, Maryland, June 18-21, 1990 [review]. J Natl Cancer Inst Monogr 1992;11:1-187.
119. Morrow M, Strom EA, Bassett LW, et al. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin 1990;52:277-300.
120. Pierce LJ, Lippman M, Ben-Baruch N, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1992;23:949-60.
121. Ring A, Smith I, Webb A, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy in early breast cancer? J Clin Oncol 2003;21:4540-45.
122. De Lena M, Varini M, Zucali R, et al. Multimodal treatment for locally advanced breast cancer. Results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981;4:229-36.
123. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G, Veronesi U. Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 1990;15:137-47.
124. Green MC, Hortobagyi GN. Chemotherapy for breast cancer. In: Hunt KK, Robb GL, Strom EA, Ueno NT. Breast Cancer. New York: Springer, 2001:309-41.
125. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52.
126. Schwartz GF. Breast conservation following induction chemotherapy for locally advanced breast cancer: a personal experience. Breast J 1996;2:78-82.
127. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119-29.
128. Wang J, Bucholz TA, Middleton LP, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002;94:3107-14.
129. Honkoop AH, Pinedo HM, De Jong JS, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997;107:211-18.
130. Chollet P, Amat S, Belembaogo E, et al. Is the Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 2003;89:1185-91.
131. Buchholz TA, Strom EA, Perkins GH, et al. Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist 2002;7:539-46.
132. Bartelink H. Post-mastectomy radiotherapy: recommended standards [review]. Ann Oncol 2000;11(suppl 3):7-11.
133. Harris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy [review]. Int J Radiat Oncol Biol Phys 1999;44:989-90.
134. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539-69.
135. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3(suppl 2):569-74.
136. Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J Clin Oncol 1997;15:207-15.
137. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver HJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation to outcome. Br J Cancer 2003;88:406-12.